Back

Comparative clinical effectiveness and safety of amiodarone versus dronedarone in patients with atrial fibrillation

31 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation management: rhythm control, outcomes, and specific populations Rhythm Control, Antiarrhythmic Drugs ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Lu-Tsen Liu

Taipei (Taiwan)

5 More presentations in this session

Presentation thumbnail
Dynamic changes in anaemia and phenotype-specific risk of adverse outcomes in patients with atrial fibrillation treated with NOACs
Doctor A. Rigutini (Perugia, IT)
Abstract Slides Video
Presentation thumbnail
The RIBAT-AFRICA-AF Registry (Registry Initiative Across Borders for Atrial Fibrillation in Africa)
Professor A. Moustaghfir (Casablanca, MA)
Abstract Slides Video
Presentation thumbnail
The placebo effect in atrial fibrillation ablation: insights from a post hoc analysis of the PFA-SHAM trial
Doctor M. Hozman (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation and early-onset cognitive decline: a multicenter 14-year cross-sectional analysis of 1,641 patients in North Macedonia
Doctor V. Zhaku (Tetovo, MK)
Abstract Slides Video
Presentation thumbnail
Early rhythm control in patients with atrial fibrillation and cancer: a subgroup analysis of the EAST-AFNET 4 trial
Doctor D. Ismaili (Hamburg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation management: rhythm control, outcomes, and specific populations

The Event

Event poster

ESC Congress 2026

31 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials
1 September 2019
thumbnail
Congress Presentation
Prognostic comparison between implantable cardioverter-defibrillator and amiodarone in cancer patients
31 August 2025
thumbnail
Congress Presentation
Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis
20 June 2025
thumbnail
Congress Presentation
Hypo- and hyperthyroidism in patients with new-onset atrial fibrillation: a nationwide study
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources